Skip to main content
OpenTrials
Completed

NCT Number: NCT05388357

AI Quantitative Coronary Angiography Versus Optical Coherent Tomography Guidance for Coronary Stent Implantation

This study is to establish the primary hypothesis thatAI -QCA guided PCI is non-inferior to Optical coherence tomography-guided Percutaneous coronary intervention regarding minimal Stent area by Final OCT and Procedural MACE

Completed

Looking for future studies?

Notify Me

Key information

About this study

  • AI-QCA-assisted DES implantation

After coronary angiography, AI-QCA software will be used to determine the lesion length and the reference vessel diameter in real time to determine the appropriate stent size for implantation. The procedure is performed as follows:

  • Select the optimal projection angle providing the best view of the lesion.
  • Provide sufficient nitroglycerin for vasodilation. If the lesion is severely stenotic, perform balloon angioplasty, followed by nitroglycerin supply.
  • Perform AI-QCA to measure the length of the lesion and the inside diameter of the proximal and distal reference vessels.
  • Determine the stent length and size according to the AI-QCA measurements. Select a stent that is 20% larger than the distal reference vessel diameter and that can provide coverage for both the proximal and distal reference vessels.
  • Perform high-pressure balloon dilation after stent implantation, with the final balloon size being 20% larger than the distal and proximal reference vessel diameters.
  • Perform a final coronary angiogram if no procedural complications are observed on the angiogram and stent expansion is confirmed.
  • Perform a final OCT to measure the stent area (mm2), the primary efficacy endpoint.
  • If significant suboptimal stent results, such as severe underexpansion, extensive strut malapposition, or major stent edge dissection, occur, additional procedures to correct them are permitted to ensure patient safety, although they are generally discouraged. (The primary endpoint will be assessed by OCT run before such correction.)
  • OCT guided DES implantation

After coronary angiography, OCT is performed to determine the appropriate stent size for implantation. After the stent procedure, OCT is performed again to check for an area that is smaller than the area of distal reference vessel and for sufficient dilatation. If necessary, high-pressure balloon dilation is performed to minimize residual stenosis. The procedure is performed as follows:

  • Select the optimal projection angle providing the best view of the lesion.
  • Provide sufficient nitroglycerin for vasodilation. If the lesion is severely stenotic, perform balloon angioplasty, followed by nitroglycerin supply.
  • Perform OCT to obtain pre-procedural images of the vessel. If there is a stenosis and OCT images cannot be obtained, perform OCT after adequate balloon angioplasty.
  • Determine the length and size of the stent to be implanted according to the OCT images. Select the stent size in consideration of the mean lumen diameter and mean external elastic lamina (EEL) diameter of the distal reference vessel. If the EEL is not observed, use a stent that is 0.25 mm larger than the mean lumen diameter. Select the length by measuring the length of the proximal and distal reference vessel segments on the OCT.
  • Perform high-pressure balloon dilation after stent implantation. Select the final balloon size by considering the inside diameters of the distal and proximal reference vessels and EEL diameter.
  • Perform OCT. If no procedure-related complications are observed and there is no underexpansion or malapposition of the stent, perform a final coronary angiogram. If procedure-related complications or underexpansion or malapposition of the stent is observed, correct it, and then perform a final OCT to measure the stent area (mm2), the primary efficacy endpoint.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men or women at least 19 years of age
  • Patients with typical symptoms or objective evidence of myocardial ischemia and eligible for coronary angioplasty.
  • Subject with severe coronary artery disease undergoing PCI
  • Written informed consent

Exclusion criteria

  • Angiographic exclusion criteria 1) Left main lesion 2) Chronic total occlusion 3)Graft vascular lesion 4) Requiring two-stent techniques for coronary bifurcation lesions 5)Any lesion characteristics resulting in the expected inability to deliver OCT catheter to the lesion ( eg,tortuosity, moderate or severe vessel calcification)
  • Acute or chronic renal dysfunction (Plasma creatinine 2.0mg/dL or more) except patients undergoing dialysis
  • Primary coronary angioplasty in ST-elevation myocardial infarction(within 12-24 hours of symptom onset)
  • Previous PCI with BVS
  • LV dysfunction (LVEF) < 30%
  • Hypersensitivity to DES and its components or there is a reason for prohibition (everolimus, cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers)
  • Patients who require surgery requiring discontinuation of antiplatelet drugs within 1 year of the procedure
  • Life expectancy < 1 year for any disease
  • Pregnancy or breast-feeding
  • Patients unsuitable for enrollment judged by the Investigator

Treatment and study plan

Intervention Procedure: PCI

Other

Percutaneous Coronary Intervention

Primary outcomes

  1. Minimal Stent Area evaluated by OCT

    Time frame: 1hour

    Minimal Stent Area evaluated by OCT after stenting of the target lesion

  2. Procedural complications

    Time frame: 24hours

    Procedural complications including angiographic dissection, perforation, or acute closure requiring active intervention after stent implantation

Secondary outcomes

  1. Procedural success

    Time frame: 24hours

    Stent expansion (≥ 90%) in final OCT assessment and successful stent delivery without target-lesion failure in 24 hours

  2. OCT endpoint

    Time frame: 24hours

    Stent expansion, stent malapposition, intra-stent tissue (plaque or thrombus) protrusion, untreated reference segment disease

  3. Angiographic endpoint

    Time frame: 24hours

    Minimal lumen diameter at the stented segment, diameter stenosis at the stented segment, acute gain at the stented segment

  4. Death

    Time frame: 6month

    All-cause death , Cardiac and non-Cardiac death

  5. MI

    Time frame: 6month

    Any MI( periprocedural/spontaneous MI), Target vessel-MI and non-target vessel-MI

  6. Stent thrombosis

    Time frame: 6month

    definite/probable

  7. Revascularization

    Time frame: 6month

    Any revascularization,Target vessel and target lesion revascularization

  8. Composite of event

    Time frame: 6month

    Composite of all-cause death, myocardial infarction, stent thrombosis, or revascularization

  9. Quality of life score assessed by the EQ-5D

    Time frame: 6month

    The EQ-5D-5L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.

    EQ-5D: the minimum and maximum values are 5 and 25 respectively. EQ VAS: the minimum and maximum values are 0 and 100 respectively.

  10. Quality of life score assessed by Health-related Quality of Life Instrument with 8 Items (HINT-8)

    Time frame: 6month

    HINT-8 was developed based on 4 health dimensions: physical, mental, social, and positive health dimensions. It consists of climbing stairs, endurance to pain, vitality, working, depression, memory, sleep, and happiness.

  11. Cost-effective analysis

    Time frame: 6month

    Cost-effective analysis based on average treatment costs for two treatment

Sponsors and collaborators

Lead sponsor

Asan Medical Center

Other

Collaborators

  • Korea Medical Device Development Fund
  • Medipixel,Inc

Registry information

Official study title

Fully Automated Quantitative Coronary Angiography Versus Optical Coherent Tomography Guidance for Coronary Stent Implantation (FLASH): Multicenter, Randomized Controlled Non-Interiority Trial

Acronym: FLASH

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
May 24, 2022
Registry last updated
Oct 24, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.